Healthcare / BiotechnologyShanghai
$16.95
+0.40 (+2.42%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-169.9M · quality 53.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.1B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-16.2%
↓Gross Margin
64.4%
↑Debt/Equity
0.09
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-29.2%
FCF CAGR
—
FCF margin
-178.4%
FCF / Net income
1.13x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $112.9M · net income $-178.5M · FCF $-201.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $112.9M | $112.9M | $80.8M | $134.6M | $318.5M |
| Net Income | $-178.5M | $-178.5M | $-93.6M | $-71.0M | $41.5M |
| EBITDA | $-165.4M | $-165.4M | $-84.2M | $-54.8M | $79.4M |
| EPS | -1.45 | -1.45 | -0.76 | -0.58 | 0.34 |
| Gross Margin | 64.4% | 64.4% | 62.6% | 77.8% | 84.1% |
| Operating Margin | -150.4% | -150.4% | -123.0% | -32.2% | 23.1% |
| Net Margin | -158.1% | -158.1% | -115.8% | -52.7% | 13.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.09 | 0.09 | 0.04 | 0.05 | 0.03 |
| Current Ratio | 1.52 | 1.52 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-201.4M | $-201.4M | $-169.9M | $26.9M | $-129.6M |
| Returns | |||||
| ROE | -16.2% | -16.2% | -7.3% | -5.2% | 2.8% |
| Valuation | |||||
| P/E | — | — | — | — | 92.94 |
| EV/EBITDA | — | — | — | — | 46.93 |
| P/B | 1.90 | 1.90 | 1.12 | 2.31 | 2.65 |
| Growth & Yield | |||||
| Revenue Growth | 39.7% | 39.7% | -40.0% | -57.7% | — |
| EPS Growth | -90.8% | -90.8% | -31.0% | -270.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+31.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.76 → -1.45
Residual
+31.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.